For your patient whose asthma is uncontrolled on current therapy and may present with...
≥2 exacerbations annually
despite maximum doses of ICS/LABA with or without systemic steroids2-5
≥150 cells/µL* (Elevated blood eosinophils)6,7(Elevated blood eosinophils)6,7
*Although not defined by clinical guidelines, one characterization of eosinophilic asthma can be a blood eosinophil count of ≥150 cells/μL.6,7
Consider that blood eosinophils can be affected by recent corticosteroid use and can naturally vary throughout the day.
FASENRA significantly reduced patients’ exacerbations and improved lung function.*1,8,9
FASENRA is the ONLY anti-eosinophil to show lung function improvement, sustained over 2 years.†‡1,8-12
*In SIROCCO (48 weeks), a 51% reduction in annual asthma exacerbation rate was observed in patients treated with FASENRA + SOC (n=267) vs placebo + SOC (n=267) (0.74 vs 1.52, P<0.0001).1,8 In CALIMA (56 weeks), a 28% reduction in annual asthma exacerbation rate was observed in patients treated with FASENRA + SOC (n=239) vs placebo + SOC (n=248) (0.73 vs 1.01, P=0.019).1,9 In SIROCCO, a significant improvement in FEV1 at Week 48 was observed in patients treated with FASENRA + SOC (n=264) vs placebo + SOC (n=261) (398 mL vs 239 mL, P=0.0006).1,8 In CALIMA, a significant improvement in FEV1 at Week 56 was observed in patients treated with FASENRA + SOC (n=238) vs placebo + SOC (n=244) (330 mL vs 215 mL, P=0.010).1,9
†Statistical significance for FEV1 improvement was established at end of treatment. Week 4 results were descriptive only. FASENRA demonstrated greater improvements in change from baseline in pre-bronchodilator FEV1 compared with placebo at Week 4 (first measured time point after administration of treatment dose) that were maintained through end of treatment in SIROCCO and CALIMA.8-10
‡Pooled analysis of adult (treated with high-dose ICS/LABA) and adolescent (treated with medium- to high-dose ICS/LABA) patients with severe asthma and baseline blood eosinophil count ≥300 cells/μL in SIROCCO and CALIMA randomized to treatment with FASENRA 30 mg SC Q8W. BORA Week 56 results are adults only.11
FASENRA significantly reduced patients’ need for OCS use.*1,13
In ZONDA (28 weeks), the primary endpoint was median percent reduction from baseline in final OCS dose while maintaining asthma control.1
93% decrease in AER leading to ER/hospitalizations (0.02) compared to placebo (0.32) in ZONDA (28 weeks)†,1,14
FASENRA (n=73); Placebo (n=75)
*In ZONDA (28 weeks), a 75% reduction in median final OCS dose was observed in patients treated with FASENRA + SOC (n=73) vs 25% reduction with placebo + SOC (n=75) (P<0.001).1,13
†The analysis of this endpoint was not multiplicity protected. Results are descriptive only.
FASENRA is the ONLY respiratory biologic that combines Q8W maintenance dosing* with at-home or in-office administration options.†1
*Every 8 weeks following the first 3 doses Q4W.1
†Dosing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.
The mechanism of action of benralizumab in asthma has not been definitively established.
CHRISTOPHER WEBBER, MD
Dr Christopher Webber is an allergist-immunologist in Colorado Springs, Colorado. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice for more than 15 years.
“Just one month after starting FASENRA, Rob's eosinophil count dropped from 1,064 to 18.
He doesn't need his daily oral steroids. He is not as worried about exacerbations. And we've seen a clinically meaningful improvement in his lung function.
Individual Results May Vary
DR WEBBER, ALLERGIST-IMMUNOLOGIST
Stay Connected with FASENRA
Sign up to receive information to learn more about FASENRA and how your patients can get the most out of what FASENRA has to offer.